Drug · DIN 02445646
FLUZONE HIGH-DOSE
INFLUENZA VIRUS VACCINE TRIVALENT TYPES A AND B (SPLIT VIRION).0.5 ML SINGLE-DOSE PREFILLED SYRINGES
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 10, 2025; first marketed September 27, 2016.
- Drug Identification Number (DIN)
- 02445646
- Company (DIN owner)
- Sanofi Vaccines Canada Ltd.Toronto, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Influenza, inactivated, split virus or surface antigen J07BB02
- Class
- Human
- Record last updated
- September 9, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| HAEMAGGLUTININ-STRAIN A (H3N2) | 60 MCG | 0.5 ML |
| HAEMAGGLUTININ-STRAIN B | 60 MCG | 0.5 ML |
| HAEMAGGLUTININ-STRAIN A (H1N1) | 60 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 10, 2017: NOC 18954New Drug Submission (NDS) · Transfer of drug identification number
- September 9, 2015: NOC 17262Supplement to a New Drug Submission (SNDS) · For active immunization against influenza caused by the specific strains of influenza virus contained in the vaccine in adults 65 years of age and older